McKesson Corporation MCK
At closeNov 5, 2026, 5:34 PM EST
After hours · Nov 5, 5:34 PM ET
- YTD
- +30.69%
- 1 year
- +26.98%
- Market cap
- 124.98B
- Revenue (ttm)
- 410.98B
- Profit margin
- 1.12%
- EPS (ttm)
- 38.77
- Shares out
- 116.59M
- P/E ratio
- 27.65
- Forward P/E
- 21.10
- Dividend
- 3.76 (0.38%)
- Ex-dividend date
- Nov 30, 2026
- YTD return
- +30.69%
- 1-year return
- +26.98%
- Volume
- 1.29M
- Avg volume
- 849.95K
- Open
- 1,085.84
- Previous close
- 1,069.44
- Day's range
- 1,072.00 – 1,121.50
- 52-week range
- 723.68 – 1,121.50
- Beta
- 0.28
- Analysts
- Buy
- Price target
- 1,026.07 (-4.3%)
- Earnings date
- Feb 3, 2027
5D +64.34 (+6.38%)
Key statistics
- Enterprise value
- 126.12B
- PEG ratio
- 1.88
- Price / sales
- 0.30
- Price / book
- 0.00
- Dividend yield
- 0.38%
- Payout ratio
- 8.79%
- Revenue growth
- 7.70%
- Free cash flow
- 6.80B
- Total cash
- 5.16B
- Total debt
- 11.80B
- Return on equity
- 0.00%
- Short % of float
- 1.97%
- 50-day average
- 927.49
- 200-day average
- 864.20
Analyst view
Consensus: buy
- Target (low)
- 845.00
- Target (mean)
- 1,026.07
- Target (high)
- 1,207.00
- Strong buy3
- Buy10
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 10.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 10.91 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 10.72 | 11.68 | +0.96 | +8.96% |
| Aug 5, 2026 | Jun 30, 2026 | 9.56 | 9.93 | +0.37 | +3.87% |
| May 7, 2026 | Mar 31, 2026 | 11.56 | 11.69 | +0.13 | +1.12% |
| Feb 4, 2026 | Dec 31, 2025 | 9.17 | 9.34 | +0.17 | +1.85% |
| Nov 5, 2025 | Sep 30, 2025 | 9.03 | 9.86 | +0.83 | +9.19% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Mizuho | main | Neutral | Neutral |
| Oct 16, 2026 | UBS | main | Buy | Buy |
| Oct 7, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 14, 2026 | RBC Capital | reit | Sector Perform | Sector Perform |
| Aug 19, 2026 | Barclays | main | Overweight | Overweight |
| Aug 19, 2026 | RBC Capital | init | — | Sector Perform |
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Website
- mckesson.com
News
TD Cowen Maintains Buy on McKesson, Raises Price Target to $1200 
Leerink Partners Maintains Outperform on McKesson, Raises Price Target to $1200 
RBC Capital Maintains Sector Perform on McKesson, Raises Price Target to $965 
MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised 
Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $1200 
McKesson Corporation (MCK) Q2 2027 Earnings Call Transcript 
Here's What Key Metrics Tell Us About McKesson (MCK) Q2 Earnings 
McKesson (MCK) Beats Q2 Earnings and Revenue Estimates 
UPDATE: McKesson Raises FY2027 Adj EPS Guidance from $44.20-$45.00 to $45.60-$46.40 vs $44.71 Est; Raises FY2027 Sales Guidance from $423.601B-$439.739B to $427.636B-$443.773B vs $432.063B Est 
McKesson Q2 2027 Earnings Call Transcript
Your note
Sign in to keep a note on MCK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARUSO DOMINIC J | Director | Stock Award(Grant) | Jul 21, 2026 | 927 |
| FRAGA FRANCISCO | Chief Technology Officer | Sale | Oct 14, 2026 | 5,423 |
| LAU MICHELE | Officer | Sale | May 25, 2026 | 3,386 |
| MARTINEZ MARIA N. | Director | Stock Award(Grant) | Jul 21, 2026 | 578 |
| RODGERS THOMAS L | Officer | Sale | Jun 1, 2026 | 2,268 |
| RUTLEDGE NAPOLEON B JR | Officer | Sale | Sep 7, 2026 | 521 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.26% | 10,795,054 | 11.53B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.74% | 7,853,137 | 8.39B | Jun 29, 2026 |
| State Street Corporation | 4.91% | 5,727,118 | 6.12B | Jun 29, 2026 |
| Morgan Stanley | 4.55% | 5,306,142 | 5.67B | Jun 29, 2026 |
| Franklin Resources, Inc. | 2.49% | 2,905,114 | 3.10B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.46% | 2,873,217 | 3.07B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27% | 3,816,285 | 4.08B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.67% | 3,114,077 | 3.33B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 1,553,893 | 1.66B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 1,515,199 | 1.62B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 1,440,411 | 1.54B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.98% | 1,144,445 | 1.22B | Jun 29, 2026 |